Oncology News

• Skinny-Label Biosimilars Provide Substantial Savings to Medicare The estimated savings to Medicare during 2015-2020 that resulted from competition with five of the first-to-market biosimilars with skinny labels was $1.5 billion.
  MDedge News, November 28, 2022
• RSNA 2022 Lung Cancer Screening Pushes 20-Year Survival Rate to 80% Results of a large, international study show the benefit of annual, low-dose CT scans for those diagnosed early persists at 20 years.
  Medscape Medical News, November 28, 2022
• 'Something Good After Tragic Loss': Donating Brain Cancer Tissue Families of children with brain cancer are often unaware of the option of postmortem tissue donation, and many have expressed resentment that they had not been informed.
  Medscape Medical News, November 28, 2022
• Transgender Patients on Hormone Therapy Require Monitoring Because of their increased risk for death, compared with the general population, transgender patients on hormone therapy need cardiovascular and cancer monitoring, according to experts.
  Medscape Medical News, November 28, 2022
• Alcohol, Melatonin, and Other Top Clinical Topics of 2022 See which studies led to the most popular clinical topics of the year, with an infographic on each of the key findings.
  Medscape, November 28, 2022
• Vitamin D Fails to Stave Off Statin-Related Muscle Symptoms A substudy of the VITAL trial provides the first randomized data examining the effect of the popular supplement on muscle symptoms in statin users.
  Medscape Medical News, November 28, 2022
• Managing T-DXd Adverse Events in the Real World Managing adverse events with trastuzumab deruxtecan (Enhertu) in real-world clinical practice is proving trickier than would have been anticipated from clinical trial reports.
  Medscape Medical News, November 25, 2022
• Alert FDA Rejects Poziotinib for Certain Types of NSCLC The drug was not approved for the treatment of patients with previously treated locally advanced or metastatic nonsmall cell lung cancer harboring HER2 exon 20 insertion mutations.
  Medscape Medical News, November 25, 2022
• FDA Requests More Restrictions on Ovarian Cancer Drugs The limits on second-line prescribing for one of the drugs, rucaparib, could put the company's financial future at risk, a company report shows.
  Medscape Medical News, November 23, 2022
• Don't Call Me 'Dr', Say Some Physicians. Most Disagree Patients "untitling" physicians has become more common. Some doctors think it's a positive trend, but others feel that the honorific title helps reinforce the physician's medical knowledge.
  Medscape Medical News, November 23, 2022
• Alert FDA Approves First Gene Therapy for Hemophilia B Etranacogene dezaparvovec is the first gene therapy option for adults with hemophilia B who use factor IX prophylaxis and have repeated, spontaneous bleeding episodes. This one-time gene therapy has a list price of $3.5 million.
  MDedge News, November 23, 2022
• Quantum Computing: Medicine's Next Great Leap Quantum computing is a completely new type of computing that has already begun to advance everything from drug development and disease identification to the security of electronic records.
  WebMD Health News, November 22, 2022
• Over Half of Targetable NSCLC Patients Miss Out on Correct Tx Most patients with advanced non–small cell lung cancer (NSCLC) have tumors with actionable mutations, but two thirds of them are not receiving targeted therapy owing to gaps in clinical practice.
  Medscape Medical News, November 22, 2022
• New Docs Find Both Fulfillment and Frustration in First Years Whether you just became an attending or have a few years under your belt, the newest generation of physicians speaks out about the good, the bad and the ugly within the medical field.
  Medscape Medical News, November 22, 2022
• ACR 2022 ACR, EULAR Roll Out Updated Antiphospholipid Syndrome Criteria A joint planning group proposes updates to 16-year-old criteria for classifying antiphospholipid syndrome.
  MDedge News, November 22, 2022
• Alert Blenrep for Multiple Myeloma Withdrawn From US Market The manufacturer is pulling the drug from the market at the request of the FDA following disappointing results from a large phase 3 confirmatory trial.
  News Alerts, November 22, 2022
• Overworked Nurses; Bacteria Resistance; and New Cancer Trials The top 3 things you should know to start your day.
  3 Things to Know Today, November 22, 2022
• Dermatologists Predict That Skin Cancer Cases Will Double Experts have drawn a correlation between the increased incidence of skin cancer and the increased intensity of UV radiation.
  Medscape Medical News, November 21, 2022
• Data Hint COVID-19 Vax May Improve Immunotherapy Efficacy in Some Patients with nasopharyngeal cancer who received the Chinese Sinovac COVID-19 vaccine did better on immune checkpoint inhibitor therapy compared with unvaccinated patients, early data suggest.
  Medscape Medical News, November 21, 2022
• Elizabeth Holmes Sentenced to 11 Yrs in Prison for Theranos Fraud 'I am devastated by my failings,' Holmes, 38, told Judge Edward Davila before sentencing. 'I have felt deep pain for what people went through because I failed them.'
  WebMD Health News, November 21, 2022